Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 11,419 matching trials from the live ClinicalTrials.gov search.

Filters: Seattle, Washington Clear all

Conditions: Heart Diseases, Aortic Stenosis, Severe
Interventions: Edwards SAPIEN 3 / SAPIEN 3 Ultra THV; Device
Lead sponsor: Edwards Lifesciences; Industry
Eligibility: 65 Years and older
Enrollment: 901 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2032
U.S. locations: 74
States / cities: Phoenix, Arizona • Burlingame, California • Los Angeles, California + 62 more

Conditions: Neuroblastoma
Interventions: 131I-MIBG, Dinutuximab, Vorinostat, Sargramostim, Potassium Iodide; Radiation · Drug
Lead sponsor: New Approaches to Neuroblastoma Therapy Consortium; Other
Eligibility: 1 Year to 30 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 12
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 9 more

Conditions: Hen Egg Allergy
Interventions: AR201 powder, Placebo powder; Biological
Lead sponsor: Aimmune Therapeutics, Inc.; Industry
Eligibility: 4 Years to 26 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 11
States / cities: Little Rock, Arkansas • Rolling Hills Estates, California • San Diego, California + 8 more

Conditions: Post-Traumatic Stress Disorder
Interventions: orvepitant, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 26
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Beverly Hills, California + 23 more

Conditions: Carotid Stenosis
Interventions: Not listed
Lead sponsor: University of Washington; Other
Eligibility: Male only
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Acute Myeloid Leukemia, Minimal Residual Disease Negativity
Interventions: Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Etoposide, Laboratory Biomarker Analysis; Procedure · Drug · Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years to 69 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Multiple Sclerosis
Interventions: 4-session Relaxation Training, 4-session Behavioral Activation, 4-session Cognitive Therapy; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Cystic Fibrosis, Colorectal Cancer, Adenoma
Interventions: Stool tests; Procedure
Lead sponsor: University of Washington, the Collaborative Health Studies Coordinating Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 26
States / cities: Los Angeles, California • Palo Alto, California • Denver, Colorado + 21 more

Conditions: Multiple Myeloma
Interventions: GSK2857916; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 6
States / cities: Boston, Massachusetts • New York, New York • Chapel Hill, North Carolina + 3 more

Conditions: Muscular Dystrophy, Duchenne, Muscular Dystrophies, Muscular Disorders, Atrophic, Muscular Diseases, Musculoskeletal Diseases, Neuromuscular Diseases, Nervous System Diseases, Genetic Diseases, X-Linked, Genetic Diseases, Inborn
Interventions: Ataluren, Placebo; Drug
Lead sponsor: PTC Therapeutics; Industry
Eligibility: 7 Years to 16 Years · Male only
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 21
States / cities: Los Angeles, California • Sacramento, California • Aurora, Colorado + 17 more

Conditions: Amyloidosis
Interventions: Cyclophosphamide, Bortezomib, Dexamethasone, 40 mg, Daratumumab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 416 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 29
States / cities: Phoenix, Arizona • Duarte, California • San Francisco, California + 22 more

Conditions: Painful Diabetic Neuropathy
Interventions: NRD135SE.1, Placebo; Drug · Other
Lead sponsor: James P. Rathmell, MD; Other
Eligibility: 18 Years and older
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 26
States / cities: San Diego, California • Clermont, Florida • Gainesville, Florida + 18 more

Conditions: Neuroblastoma
Interventions: Not listed
Lead sponsor: New Approaches to Neuroblastoma Therapy Consortium; Other
Eligibility: 31 Days to 99 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2099
U.S. locations: 16
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 13 more

Conditions: Ovarian Epithelial Cancer Stage III, Stage IV Ovarian Cancer, Stage IV Breast Cancer
Interventions: lapatinib (GW572016), Carboplatin, Paclitaxel; Drug
Lead sponsor: Swedish Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 2
States / cities: Albuquerque, New Mexico • Seattle, Washington

Conditions: Alpha-1 Antitrypsin Deficiency (AATD)
Interventions: TSRA-196; Drug
Lead sponsor: Tessera Therapeutics, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 5
States / cities: Jacksonville, Florida • Boston, Massachusetts • Rochester, Minnesota + 2 more

Conditions: Posttraumatic Stress Disorder, Depression, Suicide, Traumatic Brain Injury, Alcohol Use, Drug Use
Interventions: Stepped Care Management; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 14 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: High Grade Anal Canal Intraepithelial Neoplasia, High Grade Vulvar Squamous Intraepithelial Lesion
Interventions: Laboratory Biomarker Analysis, Placebo Administration, Questionnaire Administration, Recombinant Human Papillomavirus Nonavalent Vaccine; Other · Biological
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 27 Years to 69 Years
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 2
States / cities: Birmingham, Alabama • Seattle, Washington

Conditions: Hot Flashes
Interventions: Gabapentin Extended Release, Placebo; Drug
Lead sponsor: Depomed; Industry
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 66
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 63 more

Conditions: cGVHD
Interventions: Non-Interventional; Other
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 37
States / cities: Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 30 more

Conditions: Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Recurrent Uterine Corpus Carcinoma, Stage III Uterine Corpus Cancer AJCC v7, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Stage IV Uterine Corpus Cancer AJCC v7, Stage IVA Uterine Corpus Cancer AJCC v7, Stage IVB Uterine Corpus Cancer AJCC v7
Interventions: Carboplatin, Laboratory Biomarker Analysis, Metformin Hydrochloride, Paclitaxel, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration; Drug · Other
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 469 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 431
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 298 more

Conditions: Healthy Men, Male Contraception
Interventions: Placebo, 11βmethyl nortestosterone dodecylcarbonate; Drug
Lead sponsor: Premier Research; Other
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Torrance, California • Seattle, Washington

Conditions: Cardiac Arrest
Interventions: Therapeutic Hypothermia, Therapeutic Normothermia; Procedure · Other
Lead sponsor: University of Michigan; Other
Eligibility: 48 Hours to 18 Years
Enrollment: 295 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 33
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 29 more

Conditions: Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions: pegylated liposomal doxorubicin (PLD), VTX-2337, Placebo; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 297 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 136
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Burbank, California + 104 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Atezolizumab, Carboplatin, Cisplatin, Pemetrexed; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 578 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 26
States / cities: Los Angeles, California • Sebastopol, California • Stamford, Connecticut + 23 more

Search by objective public record fields.

EARLY TAVR: Evaluation of TAVR Compared to Surveillance for Patients With Asymptomatic Severe Aortic Stenosis

MIBG With Dinutuximab +/- Vorinostat

Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy

Orvepitant (GW823296) in Adult Post Traumatic Stress Disorder

Carotid Ultrasound Sub-Study of the Familial Atherosclerosis Study-observational Study

Stem Cell Transplant to Treat Patients With Favorable or Intermediate Risk Minimal Residual Disease Negative Acute Myeloid Leukemia

Factorial Optimization Trial to Test Cognitive Behavioral Therapy Components for Multiple Sclerosis Fatigue

Colorectal Cancer Screening in Cystic Fibrosis

Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916

Phase 3 Study of Ataluren in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)

A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis

EPPIC-Net: Novaremed Painful Diabetic Peripheral Neuropathy ISA

Neuroblastoma Biology Study

Lapatinib/Carboplatin/Paclitaxel in Previously Treated Ovarian or Breast Cancer Patients

A Study of TSRA-196 in Adults With PiZZ Alpha-1 Antitrypsin Deficiency (AATD)

Trauma Survivors Outcomes and Support Study IV

HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal Lesions

Breeze3:Study of Gabapentin Extended Release in the Treatment of Vasomotor Symptoms(Hot Flashes)in Postmenopausal Women

Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease

Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer

Single Dose, Dose-Ranging Study of 11-β Methyl Nortestosterone Dodecylcarbonate (11β-MNTDC) in Healthy Men

Therapeutic Hypothermia to Improve Survival After Cardiac Arrest in Pediatric Patients-THAPCA-OH [Out of Hospital] Trial

VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)